Scan to Download ios&Android APP

Trade ARCA Biopharma - ABIO CFD

-
0%

ARCA Biopharma live chart

Still looking for a broker you can trust?
Capital.com Group
400,000+

Traders

90,000+

Active clients monthly

$65,000,000+

Monthly investing volume

$29,000,000+

Withdrawn each month

  • Summary
  • Historical Data
Trading Conditions
Long position overnight fee
-0.0225%
Short position overnight fee
-0.0219%
Overnight fee time
21:00 (UTC)
Min traded quantity
1
Currency
USD
Margin
20%
Stock exchange
United States of America
Commission on trade
0%
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low

Content 2
Content 2

Key Stats

Prev. Close* N/A
Open* N/A
Day's Range* N/A
1-Year Change* N/A
Volume N/A
Average Vol. (3m) 3.22418
52 wk Range N/A
Market Cap 33.7197
P/E Ratio N/A
Shares Outstanding 14.41M
Revenue N/A
EPS -1.28325
Dividend (Yield %) N/A
Beta 2.19601
Next Earnings Date Aug 2, 2022

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

ARCA Biopharma Company profile

About Arca Biopharma Inc

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Arca Biopharma Inc revenues was not reported. Net loss increased 98% to $19.3M. Higher net loss reflects Other -Research and development increase from $5M to $13.7M (expense), other expenses1 increase of 8% to $5.1M (expense), Stock-based Compensation in SGA increase from $17K to $337K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.07 to -$1.39.

Equity composition

Common Stock $.001 Par, Insiders own 3.59% . IPO 8/97, 3M shares @$14 by LehmanBrothers, Inc. PO 3/04, 5M shares @ $13 by UBS SecuritiesLLC. 2/03, Company merged with Variagenics, Inc. andchanged name from Hyseq, Inc. 01/09, Name changed fromNuvelo, Inc. 03/13, 1-for-6 reverse stock split. 9/15, 1-for-7 reverse stock split.

Industry: Bio Therapeutic Drugs

Suite 430
8001 Arista Place
BROOMFIELD
COLORADO 80021
US

People Also Watch

US Tech 100

11,680.60 Price
+0.690% 1D Chg, %
Long position overnight fee -0.0092%
Short position overnight fee 0.0008%
Overnight fee time 21:00 (UTC)
Spread 1.1

Still looking for a broker you can trust?

Join the 400.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading